Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity
Peter de Boer, Wayne C. Drevets, Hany Rofael, et al.
Journal of Psychopharmacology (2018) Vol. 32, Iss. 6, pp. 668-677
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS
Brendan P. Lucey, Haiyan Liu, Cristina D. Toedebusch, et al.
Annals of Neurology (2023) Vol. 94, Iss. 1, pp. 27-40
Open Access | Times Cited: 44
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis
Tao Xue, Xin Wu, Shujun Chen, et al.
Sleep Medicine Reviews (2021) Vol. 61, pp. 101573-101573
Closed Access | Times Cited: 68
The orexin story, sleep and sleep disturbances
Fabio Pizza, Lucie Barateau, Yves Dauvilliers, et al.
Journal of Sleep Research (2022) Vol. 31, Iss. 4
Closed Access | Times Cited: 48
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
Kasper Recourt, Peter de Boer, Rob Zuiker, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Effects of orexin receptor antagonism on human sleep architecture: A systematic review
Jacob Clark, Maddison L. Brian, Sean P. A. Drummond, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101332-101332
Closed Access | Times Cited: 54
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia
Catherine Roch, Giorgio Bergamini, Michel A. Steiner, et al.
Psychopharmacology (2021) Vol. 238, Iss. 10, pp. 2693-2708
Open Access | Times Cited: 50
Lateral hypothalamus orexinergic inputs to lateral habenula modulate maladaptation after social defeat stress
Dan Wang, Ao Li, Keyi Dong, et al.
Neurobiology of Stress (2021) Vol. 14, pp. 100298-100298
Open Access | Times Cited: 46
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
Sander Brooks, Gabriël E. Jacobs, Peter de Boer, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 2, pp. 202-209
Closed Access | Times Cited: 52
Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
Adam Savitz, Ewa Wajs, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2021) Vol. 24, Iss. 12, pp. 965-976
Open Access | Times Cited: 40
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Seltorexant for major depressive disorder
K.L. Valentino, Kayla M. Teopiz, Sabrina Wong, et al.
Expert Opinion on Emerging Drugs (2025)
Closed Access
Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation
Carsten T. Beuckmann, Takashi Ueno, Makoto Nakagawa, et al.
SLEEP (2019) Vol. 42, Iss. 6
Open Access | Times Cited: 38
The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System
Jennifer E. Fragale, Morgan H. James, Jorge A. Avila, et al.
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 117-127
Open Access | Times Cited: 29
Orexin Receptor Antagonists and Insomnia
Xin Wu, Tao Xue, Zhouqing Chen, et al.
Current Psychiatry Reports (2022) Vol. 24, Iss. 10, pp. 509-521
Closed Access | Times Cited: 20
5-Amino-2-aryl-2H-1,2,3-triazole-4-carboxamides: Unique AIEE-gens and selective Hg2+ fluorosensors
Nikita E. Safronov, Артем С. Минин, Павел А. Слепухин, et al.
Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy (2023) Vol. 292, pp. 122419-122419
Closed Access | Times Cited: 12
General Synthesis of Tri-Carbo-Substituted N2-Aryl-1,2,3-triazoles via Cu-Catalyzed Annulation of Azirines with Aryldiazonium Salts
Fang‐Fang Feng, Jun‐Kuan Li, Xuan‐Yu Liu, et al.
The Journal of Organic Chemistry (2020) Vol. 85, Iss. 16, pp. 10872-10883
Closed Access | Times Cited: 26
An Update on Assessment, Therapeutic Management, and Patents on Insomnia
Amit Porwal, Yogesh Chand Yadav, Kamla Pathak, et al.
BioMed Research International (2021) Vol. 2021, pp. 1-19
Open Access | Times Cited: 21
At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities
Mark K. Greenwald, Tabitha E.H. Moses, Timothy Roehrs
Translational research (2021) Vol. 234, pp. 58-73
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top